Dechra Pharmaceuticals PLC — Director's Dealing 2016

Nov 29, 2016

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 4797Q

Dechra Pharmaceuticals PLC

29 November 2016

29 November 2016

Dechra® Pharmaceuticals PLC

(Dechra or the Company)

Notification and public disclosure of transactions by persons discharging managerial responsibilities (PDMR) and persons closely associated with them (PCA)

Exercise of LTIP options:

Dechra Pharmaceuticals PLC announces that on 28 November 2016, the following PDMRs exercised nil cost options over ordinary shares of 1p each in the Company. The options were granted to them on 27 November 2013 pursuant to the Dechra Pharmaceuticals PLC Long Term Incentive Plan (the LTIP). The exercise of the options was subject to the achievement of performance conditions which vested at 96.25% of the total award. The PDMRs named below received in satisfaction of the vesting of their awards under the LTIP the number of ordinary shares set out below:

Name	Capacity	Options Exercised	Total beneficial shareholding following this announcement	Percentage of issued share capital
Ian Page	Director	124,375	876,541	0.942%
Tony Griffin	Director	32,849	84,953	0.091%

The Notification of Dealing Forms set out below are provided in accordance with the requirements of the EU Market Abuse Regulation.

Notification of Dealing Form

1.	Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA")
a)	Name	Ian Page
2.	Reason for the notification
a)	Position/status	Director
b)	Initial notification/ amendment	Initial Notification
3.	Details of the Issuer
a)	Name	Dechra Pharmaceuticals PLC
b)	LEI code	N/A
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument Identification code	Ordinary Shares of 1 pence each ISIN: GB0009633180
b)	Nature of the transaction	Exercise of nil cost options under the Company's Long Term Incentive Plan
c)	Price(s) and volumes(s)	Price(s) Nil cost	Volume(s) 124,375
d)	Aggregated information -   Aggregate volume -   Price	N/A
e)	Date of the transaction	2016.11.28
f)	Place of the transaction	Outside a trading venue

1.	Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA")
a)	Name	Tony Griffin
2.	Reason for the notification
a)	Position/status	Director
b)	Initial notification/ amendment	Initial Notification
3.	Details of the Issuer
a)	Name	Dechra Pharmaceuticals PLC
b)	LEI code	N/A
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument Identification code	Ordinary Shares of 1 pence each ISIN: GB009633180
b)	Nature of the transaction	Exercise of nil cost options under the Company's Long Term Incentive Plan
c)	Price(s) and volumes(s)	Price(s) Nil cost	Volume(s) 32,849
d)	Aggregated information -   Aggregate volume -   Price	N/A
e)	Date of the transaction	2016.11.28
f)	Place of the transaction	Outside a trading venue

For further information, please contact:

Suzana Cross, General Counsel and Company Secretary                

Telephone number: 01606 814730

About Dechra

Dechra is an international specialist veterinary pharmaceuticals and related products business.  Our expertise is in the development, manufacture, and sales and marketing of high quality products exclusively for veterinarians worldwide. Dechra's business is unique as the majority of its products are used to treat medical conditions for which there is no other effective solution or have a clinical or dosing advantage over competitor products.  For more information please visit: www.dechra.com

Trademarks

Dechra and the Dechra "D" logo are registered trademarks of Dechra Pharmaceuticals PLC.

This information is provided by RNS

The company news service from the London Stock Exchange

END

DSHBLBPTMBMTBLF